Our latest First Rounders podcast features Neil Kumar. Here is an article in Business Insider with Neil talking about BridgeBio’s business model, and here is an Xconomy article covering BridgeBio’s ~$350 million IPO. Here is a long panel session at Biotech Showcase, with Neil talking about funding drugs for rare disease. In the podcast we discussed Andrew Lo’s “megafund” article in Nature Biotechnology, which can be read here, and also the book Scale, by Geoffrey West. The podcast itself can be found here.